🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

23 recruiting trials

for Platinum-Resistant Fallopian Tube Carcinoma

GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer NCT07489287Phase 11 site📍 Buffalo Roswell Park Cancer Institute · Tests: GB-5267 - IV only, GB-5267 -Combined IV and IP Infusion MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer NCT06483048Phase 11 site📍 Scottsdale Mayo Clinic · Tests: Autologous MUC1-activated T-cells, Bendamustine, Biospecimen Collection, Computed Tomography, Cyclophosphamide Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers NCT06906341Phase 249 sites📍 Birmingham📍 Palo Alto📍 San Francisco Corcept Therapeutics · Tests: Relacorilant 150 mg once daily (QD), Nab-paclitaxel 80 mg/m^2, Bevacizumab 10 mg/kg Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer NCT05538091Phase 21 site📍 Pittsburgh Ronald Buckanovich · Tests: Vismodegib, Atezolizumab Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors NCT05985655Phase 1, Phase 215 sites📍 Los Angeles📍 Grand Rapids📍 New York Exscientia AI Ltd., a wholly owned subsidiary of Recursion … · Tests: GTAEXS617, SoC A Study of SYS6043 in Platinum-Resistant, Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancers NCT07708753Phase 31 site📍 Beijing CSPC Megalith Biopharmaceutical Co.,Ltd. · Tests: SYS6043, Liposomal doxorubicin, paclitaxel, or topotecan HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer NCT06855069Phase 31 site📍 Beijing Hansoh BioMedical R&D Company · Tests: HS-20089, Paclitaxel, Doxorubicin, Topotecan CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer. NCT06690775Phase 266 sites📍 Phoenix📍 Tucson📍 Duarte TORL Biotherapeutics, LLC · Tests: TORL-1-23, TORL-1-23, TORL-1-23, Pegfilgrastim (drug) Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) NCT05579366Phase 1, Phase 266 sites📍 Phoenix📍 Tucson📍 Los Angeles Genmab · Tests: Rina-S, Carboplatin, Bevacizumab, Pembrolizumab, Erythromycin An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China NCT07604766Phase 317 sites📍 Changchun📍 Changsha📍 Chengdu Genmab · Tests: Rina-S, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin (PLD), Gemcitabine A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer NCT06161025Phase 2, Phase 3167 sites📍 Anchorage📍 New Haven📍 Coral Gables Daiichi Sankyo · Tests: R-DXd, Paclitaxel, Topotecan, PLD A Study of Lorigerlimab in Participants With Advanced Solid Tumors NCT06730347Phase 216 sites📍 Los Angeles📍 New Orleans📍 Grand Rapids MacroGenics · Tests: Lorigerlimab A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine NCT06682988Phase 252 sites📍 Sarasota📍 Edgewood📍 Lexington AbbVie · Tests: Mirvetuximab Soravtansine Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer NCT06787612Phase 256 sites📍 Birmingham📍 La Jolla📍 Los Angeles Regeneron Pharmaceuticals · Tests: Ubamatamab, Bevacizumab, Cemiplimab, Fianlimab, PLD Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer NCT06856499Phase 12 sites📍 Aurora📍 Aurora University of Colorado, Denver · Tests: Cirtuvivint, Olaparib A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer. NCT06434610Phase 217 sites📍 Beijing📍 Bengbu📍 Changsha Shanghai Jiaolian Drug Research and Development Co., Ltd · Tests: B013, Paclitaxel, Placebo A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression NCT07546500Phase 359 sites📍 Phoenix📍 Antioch📍 Beverly Hills K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis … · Tests: Investigator's choice of Chemotherapy, Azenosertib ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer NCT04055649Phase 22 sites📍 Detroit📍 Flint Ira Winer · Tests: Akt/ERK Inhibitor ONC201, Paclitaxel, Questionnaire Administration A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies NCT07024784Phase 221 sites📍 Los Angeles📍 Aurora📍 Minneapolis AbbVie · Tests: IMGN151, Carboplatin, Bevacizumab, Olaparib Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer NCT05231122Phase 22 sites📍 Buffalo📍 Houston Roswell Park Cancer Institute · Tests: Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Bevacizumab, Pembrolizumab, Quality-of-Life Assessment, Questionnaire A… A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors NCT06792552Phase 117 sites📍 Orlando📍 Atlanta📍 New Orleans NextCure, Inc. · Tests: SIM0505 for injection, SIM0505 for injection A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01) NCT06994195Phase 31 site📍 Shanghai Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-B01D1, Liposomal doxorubicin, Paclitaxel or Topotecan Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) NCT05281471Phase 333 sites📍 Mobile📍 Tucson📍 Duarte Genelux Corporation · Tests: olvimulogene nanivacirepvec, Platinum chemotherapy: carboplatin (preferred) or cisplatin, Non-platinum chemotherapy: Ph…
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy